Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSThe global liquid phase peptide synthesis market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The extensive deployment of liquid phase peptide synthesis in large-scale industries owing to its capability of producing a large number of high-quality peptides, are expected to fuel the growth of this market. Liquid phase peptide synthesis was the first method to be used for the generation of peptides in-vitro and is still commonly utilized for large-scale peptide synthesis required in end-user industries. It helps in performing convergent peptide synthesis in which separate peptides are synthesized and then are attached together to create larger peptides, which is why it is abundantly used for large-scale production of peptides. The growth of the market can also be attributed to factors such as the increasing use of peptides in pharmaceutical drug development, and treatment of various lifestyle disorders, such as, diabetes and obesity. According to the data collected from International Diabetes Federation, it is estimated that around 463 million people globally had diabetes in 2019, and by 2045, the count is projected to reach 700 million. Peptides have diverse biological characteristics such as high biological activity, high specificity & ample chemical space, relative ease of synthesis, easy availability, and low toxicity, which are further estimated to boost the market growth. CLICK TO DOWNLOAD SAMPLE REPORT
The global liquid phase peptide synthesis market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The extensive deployment of liquid phase peptide synthesis in large-scale industries owing to its capability of producing a large number of high-quality peptides, are expected to fuel the growth of this market. Liquid phase peptide synthesis was the first method to be used for the generation of peptides in-vitro and is still commonly utilized for large-scale peptide synthesis required in end-user industries. It helps in performing convergent peptide synthesis in which separate peptides are synthesized and then are attached together to create larger peptides, which is why it is abundantly used for large-scale production of peptides. The growth of the market can also be attributed to factors such as the increasing use of peptides in pharmaceutical drug development, and treatment of various lifestyle disorders, such as, diabetes and obesity. According to the data collected from International Diabetes Federation, it is estimated that around 463 million people globally had diabetes in 2019, and by 2045, the count is projected to reach 700 million. Peptides have diverse biological characteristics such as high biological activity, high specificity & ample chemical space, relative ease of synthesis, easy availability, and low toxicity, which are further estimated to boost the market growth.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the rising demand for novel antibody and protein-based drugs, and the easy & cost-effective procedure for liquid phase peptide synthesis in the region, backed by availability of cheap labour and raw materials. Moreover, the high prevalence of diseases, such as, diabetes in China and India is also estimated to boost the market growth. Around 60% of the population of Asia Pacific suffered from diabetes in 2019.
Furthermore, in 2030, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the favourable regulatory environment for early approval of peptide drugs, accompanied by the presence of advanced healthcare infrastructure in the region. According to the World Health Organization (WHO), 16.416 % of the GDP was spent on the healthcare sector in North America in 2018. Along with this, North America also has a high prevalence of chronic lifestyle disorders, which is also expected to boost the demand for peptides, which in turn, is expected to contribute to the market growth in the region.
Alternatively, the market in Europe is also anticipated to occupy a significant share in the liquid phase peptide synthesis market during the forecast period, on account of high use of liquid phase peptide synthesis for industrial purposes and the increased prevalence of obesity & diabetes in the region. As per the International Diabetes Federation Atlas, in 2019, around 59 million individuals in the age between 20-79 years had diabetes in Europe. Additionally, European region had the highest number of children and adolescents having Type-1 diabetes.
The global liquid phase peptide synthesis market is further classified on the basis of region as follows:
Our in-depth analysis of the global liquid phase peptide synthesis market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The extensive deployment of liquid phase peptide synthesis in large-scale industries and its capability of producing large number of high-quality peptides are the key factors driving market growth.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2022-2030.
The slow peptide production speed along with high labour requirement and dispersed regulations for therapeutic peptides are estimated to hamper the market growth.
The slow peptide production speed along with high labour requirement and dispersed regulations for therapeutic peptides are estimated to hamper the market growth.
The major players dominating the liquid phase peptide synthesis market are AAPPTec, LLC, CEM Corporation, Bachem Holding AG, Zen-Bio Inc, and CSBio, among others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, end-user, and by region.
With respect to end-user, the pharmaceutical & biotechnology industry segment is anticipated to hold the largest market share owing to growth in use of peptides for therapeutic development and ligation technologies.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
